What made me sickest over the Larry King show on prostate cancer was in the beginning of the show, when Larry King stated something along the lines that if they find the cure for prostate cancer they just might have to name it or call it the Milken cure. That set the tone for the show and the angle he was playing.

Larry King lost most of his fortune not too many years ago flipping insurance policy’s under the advice of some scammers. It worked well until he found out he was the mark. To recover, it looks like he went with Madoff, where he was once again taken to the cleaners. In Milken he finally found someone with juice. The show was packed with the mutual admiration society. Milken is doing his image rehabilitation desperately seeking a pardon. Maybe Larry will have Kerry on next (I can dream).

Larry King, Mike Milken, John McEnroe, Colin Powell, Joe Torre, Rudolph Guiliani, a cast of big mouths with not one word to say about Provenge. They are a sickening, pathetic bunch. We know Larry knows about Provenge because many of our friends and members reached out to Larry in the past and more recently before the show. Now if I were a conspiracy theorist…

They never mentioned Provenge, a non toxic, non invasive safe and effective immunotherapy that harnesses and enhances your own healthy cells to fight your own prostate cancer cells. Some men with late stage pc are living 8 years later. 1 in 6 men will get prostate cancer in their lifetime.

Provenge should be on the market by next year, in spite of Milken. His chairman, Howard Scher of the Prostate Cancer Foundation Therapeutic Consortium, and Milken’s recently departed CEO, Alison Martin of the Melanoma Research Alliance, colluded on the leaked letters that stopped Provenge dead in its tracks from reaching the 69,000+ men who have died since May 2007.

Mark Mitchell of Deep Capture recently published an exposé about Milken’s part in the death of 60,000 men and the delay of Provenge. The complete story of Dendreon is now available  21 August 2009
Read the full story

The PCF is also trying to take credit for financing Provenge? It stated this because it sent some money to the University of San Francisco back in the year 2000 for Eric Small to work on immunotherapy. In 2006 Small wrote a rather positive article stating Provenge may work. In 2007 Howie Scher and Alison Martin used that 2006 abstract against Provenge highlighting the word “may” as to say it may not work. PCF cannot take credit here. It can take credit for two of its big shots stopping Provenge which had positive Phase III trials under its belt while Asentar, Abiraterone and GVAX, treatments the PCF touted, were only finished with Phase II trials.

Furthermore, in the 2005 PCF Annual Report, Novacea and Cougar did not give any money to PCF. Dendreon donated between $25k to $50K. Cell Genesis gave between $10K to $25K.

Not only did the PCF do nothing to push for Provenge approval, they actually accepted money from Dendreon to support the PCF. It should have been the other way around. Dendreon was struggling for every dollar it could muster, and must have felt it had to make a donation to PCF too! Something stinks in the world of Milken’s philanthropy and I can smell it all the way in New Jersey.

Continue Reading Hey Larry King! Do your homework!! »

Popularity: 14%

The Sixth Circuit Court in Cincinnati, Ohio has granted the request of CareToLive to present oral argument in Appeal No. 07-4465 which is the appeal of the Southern District of Ohio Court decision (case # 07-729).

Oral arguments will be heard on July 29th at 1:30 pm at the Potter Stewart United States Court House, 100 East Fifth St., Cincinnati, Ohio.

Argument will be before a three judge panel. The identity of the three judge panel will not be identified until two weeks before the oral argument date.

Also, Thanks to all the participants that helped make the first ever Coast to Coast prostate cancer demonstrations a huge success!

Continue Reading CareToLive v. FDA — Sixth Circuit Court Grants Oral Argument in Appeal! »

Popularity: 17%

I will try to keep this brief to give a short overview of the situation. The facts are out there for anybody who wants to examine this further. You may also email us for further info.

http://youtube.com/watch?v=6Q0uQAL_YDA Video of Care To Live member Ted Girgus taken at our nationwide protest in Seattle. Ted has stage IV prostate cancer, that has metastacized to his bones. Ted and his doctor, want him on Provenge NOW! (More videos and photos coming soon)

Who We Are

Care To Live is a non profit group, who formed for the sole purpose of challenging the current status quo of the prostate cancer standard of care for end stage prostate cancer. We are trying to prod our fda, our government, our medical community, our advocacy groups, and our investment firms, into embracing the better science of immunotherapy, and to consider the people first, over their profits.

Neither the Board of Directors, nor any Care To Live member or friend, including our Attorney, Kerry Donahue, receive any salary. We are volunteers from around the world, who care about the health and well being of people everywhere and are concerned that there are better treatment options which are being overlooked. We saw the immunotherapy Provenge, and what it can do, and we feel it is our duty to stand up and fight for it. It is not easy to challenge and change the current entrenched cancer treatment options. Many of us are dedicated to stay at this until Provenge is approved. We want better, safer, more humane treatments, NOW!

We are funded by small contributions from people who want to promote Provenge and Immunotherapy as a standard of care in fighting cancer. We are joined by a few great advocacy groups who support us, such as Abigail-Alliance, A Right To Live, and the Cancer Cure Coalition. We did get some additional support from Us Too, but by and large we are mostly ignored by the advocacy groups. We can only surmise that they must perceive immunotherapy as a threat to their personal agendas.

The beauty of Care To Live is that they cannot buy our silence, and they know we will never sell out for any price. We are determined to see immunotherapy brought into the 21st century.

Dendreon, the company that discovered the immunotherapy Provenge’s targeted antigen cassette delivery system, also has similar treatments in their sight for breast, colon, ovarian, lung, kidney, and cervical cancers, etc.

Are there any treatments for end stage prostate cancer?

One new treatment has been approved by our FDA in 43 years. It is a chemotherapy, which is so toxic, that most men who understand the consequences of taking it, refuse to do so. Some men will die directly as a result of the treatment. If it is successful they can expect a life extension of an extra 2 1/2 months filled with extra pain and suffering due to the severe side effects of the chemotherapy, as the cancer and the chemotherapy ravish their bodies.

What is Provenge?

Provenge is a non invasive, non toxic, targeted immunotherapy which utilizes one’s healthy cells to fight end stage prostate cancer. It is administered in 3 infusions as an outpatient using one’s own white blood cells, to mount an attack against the cancer. Some men are living as long as 7 years after the three treatments they received 7 years prior. The side effects are usually limited to a day or two of fever and chills as your body builds up an immune response.

Can I get Provenge?

No.

Provenge went before the FDA over a year ago to apply for a license. They spent years consulting with the FDA who granted Continue Reading Denial is a River of Blood at the FDA »

Popularity: 16%

Read/Download Richard Ripp Rockville Gazette Ad richardrippgazettecolor.pdf

(click to enlarge) (available to print as a full page poster on the protest page)

Richard was featured in our Rockville/ Bethesda / Chevy Chase Gazette Ad campaign in Week #6. We so appreciate his standing up to help shed light on the Provenge fiasco and do his small part to help raise awareness of the terrible decisions that are being made at the FDA. We will miss Richard very much. Our hearts go out to his family and friends for sharing Richard with us for a little while. He was truly a great American, who stood up for the things he believed in, right up until the end.

Richard Ripp’s funeral is being held Friday May 30, 2008. How fitting that we will get to remember him during our nationwide protests. Richard Ripps name needs to resonate from one Coast to the other as we express our extreme sorrow for him and the 30,000 men who are slated to die this year from prostate cancer while Provenge, an immunotherapy shown to be safe and effective, with 10 years of trials under it belt, along with an overwhelmingly favorable FDA Advisory Panel vote, lays and rots on the shelves, with no explanation or scientific reasoning from the FDA.

PLEASE HELP US GET PROVENGE TO OUR MEN NOW!

Please join us for our Nationwide Protest of the FDA On May 30th. See details here ctlnatlprotest9.pdf and also visit our rally page for additional details http://caretolive.com/rally/

Video of the 2007 Rally at the FDA http://www.youtube.com/watch?v=UqAx7uZAS90

We have to continue doing everything we can to get Provenge to our men who are running out of hope and time. Please join with us in raising awareness for this very important issue and if you can, come out on May 30 to raise your voice to get Provenge Approved NOW!

Popularity: 16%

Please join us for our Nationwide Protest of the FDA On May 30th. See details here ctlnatlprotest9.pdf and also visit our rally page for additional details http://caretolive.com/rally/

Video of the 2007 Rally at the FDA http://www.youtube.com/watch?v=UqAx7uZAS90

The FDA’s Cancer Chief Speaks Out by Catherine Arnst
In a discussion with BusinessWeek, Dr. Richard Pazdur talks about clinical trials, small biotechs, and anxious patients
http://www.businessweek.com/bwdaily/dnflash/content/
may2008/db20080521_549448.htm

Steve Walker of Abigail Alliance writes a rebuttal:

May 23rd, 2008 at 10:32 am

With respect to the following:

We cannot approve drugs on the basis of emotion, says Pazdur. We cannot make drugs available at the expense of lowering standards of approval. difficult to argue with that logic. But it’s not likely to make cancer patients, or oncology-focused drug companies, feel any better.

To those of us who have been listening to and, much more importantly, following the actions of Dr. Pazdur over the last 7 years, his response regarding “lowering approval standards” is the kind of classic, disingenuous and condescending misdirection he is renowned for among those who have to deal with him on material matters, like approval decisions for safe and effective drugs.

Continue Reading FDA Health Czar Richard Pazdur Needs to be Replaced - He Turned His Back on the Public’s Health »

Popularity: 15%

There was ample of evidence of survival benefit conferred by Provenge as a treatment in contrast to Dr. Pazdur’s statement: “Believe me, if there were a clear survival effect, the drug would be approved,”. In fact, Dr. Pazdur’s focus on the statistical flaws showed that the main problem in the FDA drug approval process as practiced by Dr. Pazdur is a slavish following of rigid statistical rules without properly factoring in clinical knowledge required to give meaning to such numerical data.

The irony is that FDA has a process to incorporate clinical knowledge into drug evaluation. Advisory Committees made up of world-class experts are often convened to discuss clinical data and provide advices to the FDA during the evaluation of drugs up for approval. The AC convened to consider Provenge voted 17-0 that the drug was safe and 13-4 that there was substantial evidence that it was effective. When Dr. Pazdur helped rejecting Provenge, he effectively ignored that body of knowledge. He showed himself to be not only a slave to simple statistical calculations but also one who cared little for the scientific process and the needs of desperate patients.

For Provenge, the clinical data were:

1. D9901, a phase 3 trial enrolling 127 patients, whose primary endpoint, Time To Progression, barely missed statistical significance with p-value .052 and Overall Survival was highly significant with p-value .01. The survival rates at three years were 1 in 3 for patients treated with Provenge compared to 1 in 9 for patients treated with placebo. Per several sensitivity analysis performed by the FDA statisticians themselves, this trial was well run, the data self-consistent and the survival benefit unlikely to be spurious.
2. D9902a, a smaller phase 3 trial enrolling 98 patients, missed statistical significance Continue Reading FDA’s Richard Pazdur Cares Little for the Scientific Process and the Needs of Desperate Patients »

   Popularity: 13%

4/16/08 The Care To Live Awareness Campaign in the Rockville Gazette, continues to confront the FDA to address our Petition for the FDA to Reconsider their decision to delay Provenge in what was an unprecedented action by them to delay a treatment in an end stage disease where no other options exist, despite the fact that Provenge was voted 17-0 Safe and 13-4 Efficacious by an FDA Advisory Panel.

Please email, print and fax our ads to help increase awareness of the Provenge Debacle so we may reverse this tragedy. It is over a year since the Advisory Panel was convened. 30,000 American men die each year of prostate cancer. 1 in 6 men will get prostate cancer in their lifetimes. We need better, safer treatments NOW! The FDA needs to address the needs of the men with end stage prostate cancer, and allow them access to the immunotherapy Provenge IMMEDIATELY!

Stephen H. Study Died without ever receiving Provenge. Shame on those individuals at the FDA responsible for this genocide. They are so concerned about selling men drugs to enhance their sex lives, and have completely ignored the real needs of our men, the approval of drugs that have prolonged survival. Some men who received Provenge in trials are alive 6 years longer.

Week #3 Color Ad caretoliverockvillegazettesstudyad3a.pdf

Week #3 Black & White Ad caretoliverockvillegazettesstudyad3abw.pdf

Popularity: 11%

WEEK #2

Week 2 Ad Color caretoliverockvillegazette2ad.pdf

Week 2 Ad Black & White caretoliverockvillegazette2adbw.pdf

Popularity: 8%